Brooklyn ImmunoTherapeutics (BTX) Resumes Another Round on Rally: Will It Hit $15?

On Monday, the Brooklyn ImmunoTherapeutics (NYSE: BTX) stock had been in sharp focus and the rally in the stock has continued during premarket trading this morning. The stock had rallied by as high as 25% yesterday and this morning, it has gone up by another 59% in premarket trading.

The optimism around the stock among investors could be linked to the reverse merger that the company had completed last month NTN Buzztime Inc. From March 26, 2021, the stock also started trading under its new ticker symbol BTX on the New York Stock Exchange.

At the time, it was announced that Brooklyn is going to be involved with the development of the cytokine-based compound IRX 2, which is meant for the treatment of various forms of cancers. It might be a good move for investors to keep an eye on the developments surround IRX 2. It now remains to be seen if the stock can continue to add to its gains through the rest of the day.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life

Want Hot Stocks?    Yes. I Love Them No thanks